O

    OS Therapies Incorporated (OSTX)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • AMEX

    $1.69
    +0.04 (+2.74%)

    Market Cap: $76.21M

    Last updated: Sep 01, 2026 at 10:00 AM ET

    Earnings

    Performance (10Y)

    Beat Rate
    13%(1/8)
    Avg Surprise
    -67.62%
    Streak
    1 Q

    Upcoming Estimates

    Sep 30, 2026
    EPS Consensus$-0.10
    Range$-0.10 - $-0.10
    2 analysts
    EPS RevisionsNo revisions (7d)
    0
    1
    30d
    EPS Estimate Drift
    90d ago$-0.10+0.0%
    60d ago$-0.14-45.0%
    30d ago$-0.20-96.7%
    7d ago$-0.20-96.7%
    Current$-0.10
    Revenue Consensus
    $0
    Range$0 - $0
    4 analysts
    Dec 31, 2026
    EPS Consensus$-0.15
    Range$-0.19 - $-0.12
    2 analysts
    Revenue Consensus
    $-242750
    Range$-242750 - $-242750
    4 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.15---
    Sep 26EST
    		-$-0.10---
    Jun 26
    		$-0.20$-0.25+20.00%Beat-5.3%
    Mar 26
    		$-0.27$-0.19-42.11%Miss-50.0%
    Dec 25
    		$-0.41$-0.14-192.86%Miss-115.8%
    Sep 25
    		$-0.21$-0.12-75.00%Miss-16.7%
    Jun 25
    		$-0.19$-0.15-26.67%Miss+68.9%
    Mar 25
    		$-0.18$-0.11-63.64%Miss-
    Dec 24
    		$-0.19$-0.14-35.71%Miss-
    Sep 24
    		$-0.18$-0.08-125.00%Miss-
    Jun 24
    		$-0.61N/AN/ABeat-

    Key Metrics

    Valuation
    P/E Ratio-1.55EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin0.00%
    ROE-914.00%ROICN/A
    Financial Health
    Debt/EquityN/AInterest CoverageN/A
    Current Ratio0.18xQuick Ratio0.18x
    Trading Statistics
    Beta-0.73Avg Volume354.29K
    52-Week High$2.3652-Week Low$1.15

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$1.59
    SMA 20$1.60
    SMA 50$1.63
    SMA 200$1.59
    EMA 10$1.62
    EMA 20$1.60
    EMA 50$1.62
    EMA 200$1.64

    MACD

    Line: 0.01Signal: -0.01Hist: 0.02

    ADX

    ADX: 10.6+DI: 26.2-DI: 21.5

    Aroon & PSAR

    Aroon Up92.0
    Aroon Down68.0
    PSAR$1.46

    Bollinger Bands

    Upper Band$1.73
    Lower Band$1.46
    %B Position1708%(Upper)
    Band Width0.83

    RSI (14-Day)

    Neutral
    56.6

    Momentum Oscillators

    Stoch %K83.9
    Stoch %D89.1
    Williams %R-10.9
    ROC (10d)14.6%
    Momentum0.21
    CCI (20d)107.5
    MFI (14d)50.3

    Volatility Measures

    ATR (14d)$0.09(5.4%)
    StdDev (20d)0.07
    Hist Vol59.4%(High)

    Volume Flow

    VWAP$1.67
    OBV-11.9M
    AD Line-18.0M
    CMF (20d)0.263

    Volume Metrics

    Avg Vol (20d)361.3K
    Vol Ratio0.6x
    VWMA (20d)$1.58

    Pivot Points

    R3$1.78
    R2$1.73
    R1$1.69
    Pivot Point$1.64
    S1$1.60
    S2$1.55
    S3$1.51

    Advanced Oscillators

    TSI3.35
    Ultimate Osc67.0
    KST-4.06

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$0$0$0$0$0$0$0$0$0$0$0$0
    Cost of Revenue$0$0$124,938$0$0$0$1,390$0$0$0N/A$0
    Gross Profit$0$0$-124,938$0$0$0$-1,390$0$0$0N/A$0
    Operating Expenses$8.58M$10.17M$11.99M$6.88M$4.84M$5.00M$2.97M$2.44M$779,800$630,232$1.16M$622,208
    R&D$6.07M$7.35M$8.80M$3.76M$2.50M$1.31M$870,468$1.21M$396,567$361,809$1.02M$454,505
    SG&A$2.50M$2.82M$3.19M$3.12M$2.34M$3.69M$2.10M$1.23M$383,233$268,423$141,285$167,703
    Operating Income$-8,575,612$-10,167,938$-11,987,892$-6,879,595$-4,838,728$-4,999,486$-2,966,421$-2,437,393$-779,800$-630,232$-1,157,033$-622,208
    Interest Income$46$45$54$65$64$66$-1$0$1$0$0$1
    Interest Expense$5,581$75,344$1.47M$0$0$0$7,559$437,839$777,681$828,760$307,534$1.35M
    Income Before Tax$-8,632,386$-10,396,831$-13,460,833$-6,879,530$-4,536,622$-3,876,859$-2,991,234$-2,875,232$-1,557,480$-1,458,992$-1,464,566$-1,974,990
    Income Tax Expense$0$0$0$0$0$0$0$0$0$0$0$0
    Net Income$-8,632,386$-10,396,831$-13,460,833$-6,879,530$-4,536,622$-3,876,859$-2,991,234$-2,875,232$-1,557,480$-1,458,992$-1,464,566$-1,974,990
    EBITDA$-8,496,804$-10,127,622$-12,298,318$-6,754,657$-4,424,172$-3,876,230$-2,982,284$-2,099,104$-270,451$-50,801$-943,798$362,250
    EBIT$-8,626,851$-10,321,532$-13,460,887$-6,879,595$-4,536,686$-3,876,925$-2,983,674$-2,437,393$-779,800$-630,232$-1,157,033$-622,208
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about OSTX

    News

    OS Therapies Enters Open Market Sale Agreement With Jefferies

    OS Therapies has entered into an open market sale agreement with Jefferies. The article, sourced from Reuters and provided via TradingView, indicates that the full details are accessible to subscribers for unlimited access.

    TradingView•8/21/26•
    Somewhat-Bullish

    OS Therapies Launches $75 Million ATM Program Under Sales Agreement With Jefferies

    OS Therapies has launched a $75 million at-the-market equity offering program through a sales agreement with Jefferies. This program allows OS Therapies to sell common stock to raise capital for clinical development, research and development, and potential strategic investments. Jefferies will act as the sales agent, receiving a 3.0% commission on gross proceeds from the sales.

    TradingView•8/21/26•
    Neutral

    OS Therapies Releases Q2 2026 Financial Results

    OS Therapies Incorporated reported a Q2 2026 loss per share of $0.20 and a net loss of $8.6 million, an increase from the prior year, as the clinical-stage biopharmaceutical company continues to invest in treatments for osteosarcoma and other solid tumors. The company remains focused on drug development for its pipeline candidates. Despite the widening deficit, Wall Street analysts maintain a positive outlook with 7 buy ratings, 1 hold, and 0 sell recommendations.

    AlphaStreet•8/17/26•
    Somewhat-Bearish

    OS Therapies Q2 Results: Net loss widens to $8.576 million

    OS Therapies reported a widened net operating loss of $8.576 million in Q2 2026, primarily due to increased R&D and regulatory costs from its UK subsidiary. Despite this, the company secured $10 million in debt financing backed by tax refunds to extend its financial runway. Key milestones include strong 2.5-year survival data for OST-HER2 and significant regulatory alignment with the FDA, EMA, and MHRA for its Biologics License Application.

    scanx.trade•8/17/26•
    Somewhat-Bullish

    OS Therapies Reports Second Quarter 2026 Financials and Provides Business and Regulatory Updates

    OS Therapies reported financial results for Q2 2026, including a net operating loss of $8.576 million. The company provided updates on its business and regulatory efforts for OST-HER2, aiming for BLA submission under the FDA's Accelerated Approval Program and Conditional Marketing Authorizations in the U.K. and Europe, supported by recent debt financing and VAT refunds. Key milestones include upcoming meetings with regulatory bodies to align on statistical methods and confirmatory trial designs.

    TMX Newsfile•8/17/26•
    Bullish

    Frequently Asked Questions About OSTX

    Does OSTX pay dividends?
    OS Therapies Incorporated (OSTX) does not currently pay a regular dividend.
    What is OSTX's market cap?
    OS Therapies Incorporated (OSTX) has a market capitalization of $76.21M with a current stock price of $1.69.

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In